Aminologics Co.Ltd (074430) - Cash Flow Conversion Efficiency

Latest as of March 2026: 0.081x

Based on the latest financial reports, Aminologics Co.Ltd (074430) has a cash flow conversion efficiency ratio of 0.081x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩4.62 Billion ≈ $3.13 Million USD) by net assets (₩57.11 Billion ≈ $38.71 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Aminologics Co.Ltd for the company's overall valuation and market capitalisation.

Aminologics Co.Ltd - Cash Flow Conversion Efficiency Trend (2008–2025)

This chart illustrates how Aminologics Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Aminologics Co.Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Aminologics Co.Ltd ranked by their cash flow conversion efficiency. Explore Aminologics Co.Ltd cash earnings quality to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Nature Holdings Co. Ltd.
KQ:298540
0.027x
LeonaBio, Inc.
NASDAQ:LONA
-0.424x
Anam Electroni
KO:008700
-0.077x
Dawonsys Co.Ltd
KQ:068240
0.103x
Alterity Therapeutics Limited
F:PBN
-0.093x
Futebol Clube do Porto - Futebol S.A.D.
LS:FCP
-0.266x
Where Food Comes From Inc
NASDAQ:WFCF
0.106x
Arizona Gold & Silver Inc.
V:AZS
-0.042x

Annual Cash Flow Conversion Efficiency for Aminologics Co.Ltd (2008–2025)

The table below shows the annual cash flow conversion efficiency of Aminologics Co.Ltd from 2008 to 2025. View Aminologics Co.Ltd stock quote for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 ₩55.99 Billion
≈ $37.95 Million
₩2.54 Billion
≈ $1.72 Million
0.045x -68.58%
2024-12-31 ₩51.70 Billion
≈ $35.03 Million
₩7.47 Billion
≈ $5.06 Million
0.144x +3702.19%
2023-12-31 ₩54.41 Billion
≈ $36.87 Million
₩-218.15 Million
≈ $-147.84K
-0.004x -103.94%
2022-12-31 ₩51.40 Billion
≈ $34.84 Million
₩5.23 Billion
≈ $3.54 Million
0.102x +545.46%
2021-12-31 ₩59.39 Billion
≈ $40.25 Million
₩935.52 Million
≈ $633.99K
0.016x -52.29%
2020-12-31 ₩53.56 Billion
≈ $36.30 Million
₩1.77 Billion
≈ $1.20 Million
0.033x -52.50%
2019-12-31 ₩51.85 Billion
≈ $35.14 Million
₩3.60 Billion
≈ $2.44 Million
0.070x -18.90%
2018-12-31 ₩53.19 Billion
≈ $36.04 Million
₩4.56 Billion
≈ $3.09 Million
0.086x +28.94%
2017-12-31 ₩45.14 Billion
≈ $30.59 Million
₩3.00 Billion
≈ $2.03 Million
0.066x -28.45%
2016-12-31 ₩44.55 Billion
≈ $30.19 Million
₩4.14 Billion
≈ $2.80 Million
0.093x +132.53%
2015-12-31 ₩48.28 Billion
≈ $32.72 Million
₩1.93 Billion
≈ $1.31 Million
0.040x +161.59%
2014-12-31 ₩31.85 Billion
≈ $21.58 Million
₩-2.07 Billion
≈ $-1.40 Million
-0.065x -127.90%
2008-12-31 ₩52.44 Billion
≈ $35.54 Million
₩12.19 Billion
≈ $8.26 Million
0.233x --

About Aminologics Co.Ltd

KQ:074430 Korea Pharmaceuticals
Market Cap
$65.27 Million
₩96.32 Billion KRW
Market Cap Rank
#20956 Global
#1193 in Korea
Share Price
₩1024.00
Change (1 day)
+2.61%
52-Week Range
₩863.00 - ₩1838.00
All Time High
₩4305.00
About

Aminologics Co.,Ltd., a specialty amino acid provider, develops a range of amino-acid-based raw materials for pharmaceutical and fine chemical industries in South Korea. Its products include D-phenylalanine, D-alanine, D-cysteine, D-serine, D-allo-isoleucine, D-allo-threonine, S-beta-phenylalanine, 3-(2-napthyl)-D-alanine, 4-chloro-D-phenylalanine, 3-(2-napthyl)-L-alanine, R-beta-phenylalanine, D… Read more